vs
FIRST HAWAIIAN, INC.（FHB）与再鼎医药（ZLAB）财务数据对比。点击上方公司名可切换其他公司
FIRST HAWAIIAN, INC.的季度营收约是再鼎医药的1.7倍（$220.3M vs $127.1M），过去两年再鼎医药的营收复合增速更高（20.8% vs 3.8%）
第一夏威夷公司是总部位于夏威夷檀香山的银行控股企业，核心子公司第一夏威夷银行成立于1858年，是夏威夷历史最悠久、规模最大的金融机构，总部设在檀香山第一夏威夷中心。该行在夏威夷设有57家分支机构，关岛有3家，塞班岛有1家，为个人及商业客户提供存款、贷款、财富管理、保险、私人银行等多元金融服务。
再鼎医药是一家创新生物制药企业，专注于肿瘤、自身免疫性疾病、感染性疾病等领域创新疗法的研发、生产与商业化，核心市场覆盖大中华区，与全球多家头部生物科技企业合作，为存在未被满足医疗需求的患者提供治疗方案。
FHB vs ZLAB — 直观对比
营收规模更大
FHB
是对方的1.7倍
$127.1M
两年增速更快
ZLAB
近两年复合增速
3.8%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $220.3M | $127.1M |
| 净利润 | $67.8M | — |
| 毛利率 | — | 51.0% |
| 营业利润率 | — | -54.6% |
| 净利率 | 30.8% | — |
| 营收同比 | — | 17.1% |
| 净利润同比 | 14.4% | — |
| 每股收益（稀释后） | $0.55 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收FHBZLAB
| Q1 26 | $220.3M | — | ||
| Q4 25 | $225.9M | $127.1M | ||
| Q3 25 | $226.4M | $115.4M | ||
| Q2 25 | $217.5M | $109.1M | ||
| Q1 25 | $211.0M | $105.7M | ||
| Q4 24 | $188.1M | $108.5M | ||
| Q3 24 | $210.0M | $101.8M | ||
| Q2 24 | $204.6M | $100.1M |
净利润FHBZLAB
| Q1 26 | $67.8M | — | ||
| Q4 25 | $69.9M | — | ||
| Q3 25 | $73.8M | $-36.0M | ||
| Q2 25 | $73.2M | $-40.7M | ||
| Q1 25 | $59.2M | $-48.4M | ||
| Q4 24 | $52.5M | — | ||
| Q3 24 | $61.5M | $-41.7M | ||
| Q2 24 | $61.9M | $-80.3M |
毛利率FHBZLAB
| Q1 26 | — | — | ||
| Q4 25 | — | 51.0% | ||
| Q3 25 | — | 59.5% | ||
| Q2 25 | — | 60.6% | ||
| Q1 25 | — | 63.6% | ||
| Q4 24 | — | 61.5% | ||
| Q3 24 | — | 64.1% | ||
| Q2 24 | — | 64.9% |
营业利润率FHBZLAB
| Q1 26 | — | — | ||
| Q4 25 | 41.2% | -54.6% | ||
| Q3 25 | 42.5% | -42.3% | ||
| Q2 25 | 40.5% | -50.3% | ||
| Q1 25 | 36.5% | -53.3% | ||
| Q4 24 | 34.4% | -62.6% | ||
| Q3 24 | 36.4% | -66.6% | ||
| Q2 24 | 39.5% | -76.0% |
净利率FHBZLAB
| Q1 26 | 30.8% | — | ||
| Q4 25 | 31.0% | — | ||
| Q3 25 | 32.6% | -31.2% | ||
| Q2 25 | 33.7% | -37.3% | ||
| Q1 25 | 28.1% | -45.8% | ||
| Q4 24 | 27.9% | — | ||
| Q3 24 | 29.3% | -40.9% | ||
| Q2 24 | 30.3% | -80.2% |
每股收益（稀释后）FHBZLAB
| Q1 26 | $0.55 | — | ||
| Q4 25 | $0.56 | $-0.05 | ||
| Q3 25 | $0.59 | $-0.03 | ||
| Q2 25 | $0.58 | $-0.04 | ||
| Q1 25 | $0.47 | $-0.04 | ||
| Q4 24 | $0.41 | $-0.09 | ||
| Q3 24 | $0.48 | $-0.04 | ||
| Q2 24 | $0.48 | $-0.08 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $689.6M |
| 总债务越低越好 | $0 | — |
| 股东权益账面价值 | $2.8B | $715.5M |
| 总资产 | $24.3B | $1.2B |
| 负债/权益比越低杠杆越低 | 0.00× | — |
8季度趋势，按日历期对齐
现金及短期投资FHBZLAB
| Q1 26 | — | — | ||
| Q4 25 | — | $689.6M | ||
| Q3 25 | — | $717.2M | ||
| Q2 25 | — | $732.2M | ||
| Q1 25 | — | $757.3M | ||
| Q4 24 | — | $779.7M | ||
| Q3 24 | — | $616.1M | ||
| Q2 24 | — | $630.0M |
总债务FHBZLAB
| Q1 26 | $0 | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
股东权益FHBZLAB
| Q1 26 | $2.8B | — | ||
| Q4 25 | $2.8B | $715.5M | ||
| Q3 25 | $2.7B | $759.9M | ||
| Q2 25 | $2.7B | $791.7M | ||
| Q1 25 | $2.6B | $810.8M | ||
| Q4 24 | $2.6B | $840.9M | ||
| Q3 24 | $2.6B | $667.7M | ||
| Q2 24 | $2.6B | $704.2M |
总资产FHBZLAB
| Q1 26 | $24.3B | — | ||
| Q4 25 | $24.0B | $1.2B | ||
| Q3 25 | $24.1B | $1.2B | ||
| Q2 25 | $23.8B | $1.2B | ||
| Q1 25 | $23.7B | $1.2B | ||
| Q4 24 | $23.8B | $1.2B | ||
| Q3 24 | $23.8B | $985.3M | ||
| Q2 24 | $24.0B | $987.4M |
负债/权益比FHBZLAB
| Q1 26 | 0.00× | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $-26.0M |
| 自由现金流经营现金流 - 资本支出 | — | $-26.7M |
| 自由现金流率自由现金流/营收 | — | -21.0% |
| 资本支出强度资本支出/营收 | — | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-158.9M |
8季度趋势，按日历期对齐
经营现金流FHBZLAB
| Q1 26 | — | — | ||
| Q4 25 | $335.1M | $-26.0M | ||
| Q3 25 | $57.1M | $-32.0M | ||
| Q2 25 | $136.4M | $-31.0M | ||
| Q1 25 | $36.7M | $-61.7M | ||
| Q4 24 | $317.5M | $-55.8M | ||
| Q3 24 | $58.9M | $-26.8M | ||
| Q2 24 | $78.2M | $-42.2M |
自由现金流FHBZLAB
| Q1 26 | — | — | ||
| Q4 25 | $303.3M | $-26.7M | ||
| Q3 25 | $49.5M | $-35.0M | ||
| Q2 25 | $125.2M | $-33.9M | ||
| Q1 25 | $28.6M | $-63.2M | ||
| Q4 24 | $288.7M | $-58.4M | ||
| Q3 24 | $52.3M | $-28.2M | ||
| Q2 24 | $72.2M | $-42.9M |
自由现金流率FHBZLAB
| Q1 26 | — | — | ||
| Q4 25 | 134.3% | -21.0% | ||
| Q3 25 | 21.9% | -30.4% | ||
| Q2 25 | 57.5% | -31.1% | ||
| Q1 25 | 13.6% | -59.9% | ||
| Q4 24 | 153.5% | -53.8% | ||
| Q3 24 | 24.9% | -27.7% | ||
| Q2 24 | 35.3% | -42.9% |
资本支出强度FHBZLAB
| Q1 26 | — | — | ||
| Q4 25 | 14.1% | 0.5% | ||
| Q3 25 | 3.3% | 2.6% | ||
| Q2 25 | 5.2% | 2.6% | ||
| Q1 25 | 3.8% | 1.5% | ||
| Q4 24 | 15.3% | 2.4% | ||
| Q3 24 | 3.1% | 1.3% | ||
| Q2 24 | 2.9% | 0.7% |
现金转化率FHBZLAB
| Q1 26 | — | — | ||
| Q4 25 | 4.79× | — | ||
| Q3 25 | 0.77× | — | ||
| Q2 25 | 1.86× | — | ||
| Q1 25 | 0.62× | — | ||
| Q4 24 | 6.05× | — | ||
| Q3 24 | 0.96× | — | ||
| Q2 24 | 1.26× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
FHB
| Net Interest Income | $167.5M | 76% |
| Noninterest Income | $52.8M | 24% |
ZLAB
| Zejula | $56.0M | 44% |
| Other | $21.9M | 17% |
| Nuzyra | $16.0M | 13% |
| Optune | $11.9M | 9% |
| XACDURO | $10.7M | 8% |
| Qinlock | $9.7M | 8% |
| AUGTYRO | $836.0K | 1% |
